Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...

Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma: Rahway, New Jersey Thursday, October 3, 2024, 10:00 Hrs [IST] Merck, known as ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK), a global healthcare leader, has completed the acquisition of a novel bispecific antibody, CN201, from Curon ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK), a global healthcare leader, has completed the acquisition of a novel bispecific antibody, CN201, from Curon Biopharmaceutical, enhancing its pipeline with ...

Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline Merck (NYSE ...

Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline ...

Avery Dennison Corporation , a leading global materials science and digital identification solutions company, today announced it will host its third quarter 2024 earnings conference call at 11:00 a.m.

Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical findings for ...

The international biopharmaceutical company Merck Group (MSD outside the USA and Canada) has entered into a final agreement with the Chinese private biotechnology company Curon Biopharmaceutical to ...